Treatment Outcomes following XXXX .

@entity1018 @entity1 @entity227 @entity228 @entity1781 @entity130 @entity288
BACKGROUND: @entity1781 is characterized by @entity1018 following facial @entity130 leading to variable @entity227 . The purpose of this study was to evaluate recent institutional trends in the treatment of @entity1781 , evaluate the outcomes of different treatment strategies, and identify factors associated with improved vision. METHODS: Institutional review board approval was obtained to retrospectively review @entity1 diagnosed with @entity1781 at a high-volume @entity130 center from 2004 to 2012. Pretreatment and posttreatment visual acuity was compared using quantitative analysis of standard ophthalmologic conversion. RESULTS: A total of 109 @entity1 met inclusion criteria (74.3 percent male @entity1 ), with a mean age of 38.0    17.5 years (range, 8 to 82 years). Management of @entity1781 involved intravenous @entity288 alone in 8.3 percent of @entity1 (n = 9), 56.9 percent (n = 62) underwent observation, 28.4 percent (n = 31) had surgical intervention, and 6.4 percent (n = 7) underwent surgery and corticosteroid administration. Only 19.3 percent of @entity1 returned for follow-up. Vision improved in 47.6 percent of @entity1 , with a mean follow-up of 12.9 weeks. @entity1 younger than 50 years had a trend toward higher rates of visual improvement, 60 percent versus 16.7 percent (p = 0.15). CONCLUSIONS: The majority of @entity1781 @entity1 are unlikely to return for a follow-up examination. Optic nerve decompression has fallen out of favor in the authors' institution, and observation is the most common management strategy. Outcomes following @entity228 administration and observation are comparable. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
